secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001193125-23-120045
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 2.02, 2.03, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics announces FDA approval of VOWST for C. diff prevention and $250M Oaktree credit facility
--------------------------------------------------------------------------------

- FDA approved VOWST (fecal microbiota spores) to prevent recurrent C. difficile infection; launch expected June 2023.
- $125M milestone payment due from Nestlé under joint commercialization agreement upon approval.
- Entered $250M Oaktree credit facility; initial $110M tranche funded, net proceeds ~$50M after repaying Hercules debt.
- Issued warrants to lenders for 647,589 shares at $6.69/share; additional warrants tied to future tranches.
- Preliminary cash and equivalents ~$107M as of March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523120045/0001193125-23-120045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523120045/d200991d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-120045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer